Oncology Drugs Market
Oncology Drugs Market Size, Share & Trends Analysis Report by Cancer Type (Lung, Breast, Colorectal, Prostate, Blood, Liver, Others), by Drug Class (Chemotherapy, Targeted Therapy, Immunotherapy, Hormonal Therapy), by Molecule Type (Small Molecules, Biologics), and Forecast Period (2026–2035)
Industry Overview
Oncology drugs market was valued at $230 billion in 2025 and is projected to reach $555 billion by 2035, growing at a CAGR of 9.2%. Market expansion is primarily driven by the rising prevalence of cancer, technological advancements in biologics, and the growing adoption of precision medicine. Immunotherapies and targeted therapies are increasingly replacing traditional chemotherapy, offering improved survival outcomes and reduced toxicity. Additionally, the expanding pipeline of monoclonal antibodies and CAR-T therapies is accelerating innovation and shaping the future of cancer treatment. Recent clinical advancements highlight this trend. In February 2026, at the ASCO Genitourinary (GU) Cancers Symposium, Merck presented data showing that KEYTRUDA plus Padcev significantly improved event-free survival and overall survival in cisplatin-eligible patients with muscle-invasive bladder cancer. Late-breaking results also demonstrated enhanced disease-free survival with WELIREG (belzutifan) plus KEYTRUDA in earlier-stage kidney cancer and progression-free survival benefits for WELIREG plus LENVIMA in advanced renal cell carcinoma, reflecting progress across genitourinary cancers.
In the same month, AstraZeneca announced that its immunotherapy Imfinzi (durvalumab), in combination with standard FLOT chemotherapy, received a recommendation from the EU CHMP for perioperative treatment of adults with resectable early-stage and locally advanced gastric and gastroesophageal junction cancers. Phase III trial data demonstrated significant reductions in disease progression, recurrence, and mortality compared to chemotherapy alone. These developments underscore the impact of strong R&D investments, regulatory support, and capacity expansion strategies by leading companies, further fueling growth in the oncology drugs market.
Market Dynamics
Lung Cancer Remains the Leading Oncology Indication Amid Advancements in Precision Therapy
Lung cancer remains the leading oncology indication due to its high global incidence and mortality rates. The expanding patient population drives strong demand for targeted therapies, immunotherapies, and combination treatments, while ongoing innovation and early detection efforts continue to broaden treatment options and market growth. In March 2026, the American Society of Clinical Oncology (ASCO) updated its living guidelines for advanced-stage IV non-small cell lung cancer (NSCLC) without driver mutations, providing more nuanced, evidence-based recommendations for treatment decisions. The updated guidance emphasizes molecular testing and PD-L1–based patient stratification to optimize immunotherapy and combination therapy selection, though frontline treatment recommendations largely remain unchanged.
Immunotherapy Takes Centre Stage in Oncology, Surpassing Traditional Cancer Treatments
Immunotherapy dominates the global oncology drugs market, fueled by a growing number of regulatory approvals and strong clinical outcomes across diverse cancer types. Innovative treatments such as checkpoint inhibitors, CAR-T therapies, and cancer vaccines are increasingly favored over traditional chemotherapy, driving widespread adoption. Ongoing research and expanding treatment indications are expected to further solidify its market leadership. According to the Cancer Research Institute, clinical adoption of immunotherapy has risen substantially across multiple cancers and is projected to continue its upward trend. Enhanced patient outcomes and broader treatment accessibility are key factors supporting the sustained growth of the immunotherapy segment within the oncology drugs market.
Market Segmentation
- Based on cancer type, the market is segmented into lung cancer, breast cancer, colorectal cancer, prostate cancer, blood cancer, liver cancer, and others.
- Based on drug class, the market is segmented into chemotherapy, targeted therapy, immunotherapy, and hormonal therapy.
- Based on molecule type, the market is segmented into small molecules and biologics.
Biologics Redefine: Monoclonal Antibodies and Cell Therapies Drive Market Growth
Biologics dominate the oncology drugs market by molecule type, driven primarily by monoclonal antibodies and CAR-T therapies. These advanced therapies provide targeted, highly effective treatment options across a wide range of cancer types, leading to improved patient outcomes. Rising regulatory approvals, strong clinical success, and growing adoption in advanced cancers continue to propel the biologics segment. According to the European Federation of Pharmaceutical Industries and Associations (EFPIA), the Comparator Report on Cancer in Europe 2025 indicates that cancer is projected to become the leading cause of death in Europe, with incidence increasing sharply. The report also notes that healthcare spending on cancer care has more than doubled over the past two decades, though access to new cancer medicines still varies significantly between Western and Central/Eastern European countries, highlighting ongoing disparities in treatment availability.
Regional Outlook
The global oncology drugs market is further divided by region, including North America (the US and Canada), Europe (the UK, Germany, France, Italy, Spain, Russia, and the Rest of Europe), Asia-Pacific (India, China, Japan, South Korea, Australia and New Zealand, ASEAN Countries, and the Rest of Asia-Pacific), and the Rest of the World (the Middle East & Africa, and Latin America).
North America is the leading region in the market
North America leads the global oncology drugs market due to high healthcare expenditure, advanced medical infrastructure, and early adoption of innovative therapies. The region benefits from a strong presence of leading pharmaceutical companies, driving research, regulatory approvals, and the commercialization of oncology drugs. These factors collectively sustain their market dominance. In November 2025, at ASH 2025, Gilead Sciences and its unit Kite presented new cell therapy data highlighting continued progress in blood cancer care. The updates reinforced the curative potential of Yescarta (axicabtagene ciloleucel). They showed promising results from next-generation CAR-T therapies targeting relapsed or refractory hematologic malignancies, underscoring North America’s leadership in innovative oncology treatments.
Market Players Outlook
The major companies operating in the global oncology drugs market include Merck & Co., Inc., Johnson and Johnson, AstraZeneca, Roche Holding AG, Pfizer Inc., Novartis AG, and Bristol Myers Squibb, among others. Market players are leveraging partnerships, collaborations, mergers, and acquisition strategies for business expansion and innovative Protection development to maintain their market positioning.
Recent Development
- In September 2024, Pfizer Inc. highlighted its diverse oncology portfolio and combination therapy approaches at ESMO 2024, featuring more than 50 research abstracts covering approved and investigational treatments across tumour types. The company showcased longer?term data for BRAFTOVI + MEKTOVI in BRAF?mutant metastatic NSCLC and encouraging early results for novel antibody?drug conjugates (ADCs) and CDK inhibitors, underscoring its commitment to advancing targeted and immuno?oncology therapies.
- In April 2025, Bristol Myers Squibb announced that the U.S. Food and Drug Administration approved Opdivo (nivolumab) plus Yervoy (ipilimumab) as a first?line treatment for unresectable or metastatic hepatocellular carcinoma (HCC) based on superior overall survival and response rates from the Phase?3 CheckMate?9DW trial. The dual immunotherapy demonstrated a significant survival benefit versus standard therapy, offering a new frontline option for liver cancer patients.
The Report Covers
- Market value data analysis of 2025 and forecast to 2035.
- Annualized market revenues ($ million) for each market segment.
- Country-wise analysis of major geographical regions.
- Key companies operating in the global oncology drugs market
- Based on the availability of data, information related to new Protections and relevant news is also available in the report.
- Analysis of business strategies by identifying the key market segments positioned for strong growth in the future.
- Analysis of market-entry and market expansion strategies.
- Competitive strategies by identifying ‘who-stands-where’ in the market.
- Report Summary
- Current Industry Analysis and Growth Potential Outlook
- Oncology Drug Market Sales Analysis – Cancer Type | Therapy | Molecule Type ($ Million)
- Oncology Drug Market Sales Market Sales Performance of Top Countries
- Research Methodology
- Primary Research Approach
- Secondary Research Approach
- Market Snapshot
- Market Overview and Insights
- Scope of the Study
- Analyst Insight & Current Market Trends
- Key Oncology Drug Market Trends
- Market Recommendations
- Market Determinants
- Market Drivers
- Drivers For Oncology Drug Market: Impact Analysis
- Market Pain Points and Challenges
- Restraints For Oncology Drug Market: Impact Analysis
- Market Opportunities
- Opportunities For Oncology Drug Market: Impact Analysis
- Market Drivers
- Competitive Landscape
- Competitive Dashboard – Oncology Drug Market Revenue and Share by Manufacturers
- Oncology Drug Type Comparison Analysis
- Top Market Player Ranking Matrix
- Key Company Analysis
- Merck & Co., Inc.
- Overview
- Product Portfolio
- Financial Analysis
- SWOT Analysis
- Business Strategy
- Johnson and Johnson
- Overview
- Product Portfolio
- Financial Analysis
- SWOT Analysis
- Business Strategy
- Bristol Myers Squibb Co.
- Overview
- Product Portfolio
- Financial Analysis
- SWOT Analysis
- Business Strategy
- Pfizer Inc.
- Overview
- Product Portfolio
- Financial Analysis
- SWOT Analysis
- Business Strategy
- Novartis AG
- Overview
- Product Portfolio
- Financial Analysis
- SWOT Analysis
- Business Strategy
- Roche Holding AG
- Overview
- Product Portfolio
- Financial Analysis
- SWOT Analysis
- Business Strategy
- Merck & Co., Inc.
- Key Company Analysis
- Top Winning Strategies by Market Players
- Merger and Acquisition
- Product Launch
- Partnership And Collaboration
- Oncology Drug Market Sales Analysis By Cancer Type ($ Million)
- Lungs Cancer
- Breast Cancer
- Colorectal Cancer
- Prostate Cancer
- Blood Cancer
- Liver Cancer
- Others
- Oncology Drug Market Sales Analysis By Therapy ($ Million)
- Chemotherapy
- Targeted Therapy
- Immunotherapy
- Hormonal Therapy
- Oncology Drug Market Sales Analysis By Molecule Type ($ Million)
- Small Molecules
- Biologics
- Regional Analysis
- North American Oncology Drug Market Sales Analysis – Cancer Type | Therapy | Molecule Type| Country ($ Million)
- Macroeconomic Factors for North America
- United States
- Canada
- European Oncology Drug Market Sales Analysis – Cancer Type | Therapy | Molecule Type| Country ($ Million)
- Macroeconomic Factors for Europe
- UK
- Germany
- Italy
- Spain
- France
- Russia
- Rest of Europe
- Asia-Pacific Oncology Drug Market Sales Analysis – Cancer Type | Therapy | Molecule Type| Country ($ Million)
- Macroeconomic Factors for Asia-Pacific
- China
- Japan
- South Korea
- India
- Australia & New Zealand
- ASEAN Countries (Thailand, Indonesia, Vietnam, Singapore, And Other)
- Rest of Asia-Pacific
- Rest of the World Oncology Drug Market Sales Analysis – Cancer Type | Therapy | Molecule Type | Country ($ Million)
- Macroeconomic Factors for the Rest of the World
- Latin America
- Middle East and Africa
- Company Profiles
- AbbVie Inc.
- Quick Facts
- Company Overview
- Product Portfolio
- Business Strategies
- Amgen Inc.
- Quick Facts
- Company Overview
- Product Portfolio
- Business Strategies
- Astellas Pharma Inc.
- Quick Facts
- Company Overview
- Product Portfolio
- Business Strategies
- AstraZeneca plc
- Quick Facts
- Company Overview
- Product Portfolio
- Business Strategies
- Bayer AG
- Quick Facts
- Company Overview
- Product Portfolio
- Business Strategies
- BeiGene Ltd.
- Quick Facts
- Company Overview
- Product Portfolio
- Business Strategies
- Blueprint Medicines Corporation
- Quick Facts
- Company Overview
- Product Portfolio
- Business Strategies
- Bristol Myers Squibb
- Quick Facts
- Company Overview
- Product Portfolio
- Business Strategies
- Daiichi Sankyo Company
- Quick Facts
- Company Overview
- Product Portfolio
- Business Strategies
- Eli Lilly and Company
- Quick Facts
- Company Overview
- Product Portfolio
- Business Strategies
- Exelixis Inc.
- Quick Facts
- Company Overview
- Product Portfolio
- Business Strategies
- Gilead Sciences, Inc.
- Quick Facts
- Company Overview
- Product Portfolio
- Business Strategies
- Hutchmed (China) Limited
- Quick Facts
- Company Overview
- Product Portfolio
- Business Strategies
- Incyte Corporation
- Quick Facts
- Company Overview
- Product Portfolio
- Business Strategies
- Ipsen Group
- Quick Facts
- Company Overview
- Product Portfolio
- Business Strategies
- Johnson & Johnson
- Quick Facts
- Company Overview
- Product Portfolio
- Business Strategies
- Merck & Co., Inc.
- Quick Facts
- Company Overview
- Product Portfolio
- Business Strategies
- Novartis AG
- Quick Facts
- Company Overview
- Product Portfolio
- Business Strategies
- Pfizer Inc.
- Quick Facts
- Company Overview
- Product Portfolio
- Business Strategies
- Regeneron Pharmaceuticals
- Quick Facts
- Company Overview
- Product Portfolio
- Business Strategies
- Roche Holding AG
- Quick Facts
- Company Overview
- Product Portfolio
- Business Strategies
- Sanofi S.A.
- Quick Facts
- Company Overview
- Product Portfolio
- Business Strategies
- Seagen Inc.
- Quick Facts
- Company Overview
- Product Portfolio
- Business Strategies
- Servier Pharmaceuticals
- Quick Facts
- Company Overview
- Product Portfolio
- Business Strategies
- Takeda Pharmaceutical Company
- Quick Facts
- Company Overview
- Product Portfolio
- Business Strategies
- AbbVie Inc.
1. Global Oncology Drug Market Research and Analysis By Cancer Type, 2025-2035 ($ Million)
2. Global Lung Cancer Drug Market Research and Analysis By Region, 2025-2035 ($ Million)
3. Global Breast Cancer Drug Market Research and Analysis By Region, 2025-2035 ($ Million)
4. Global Colorectal Cancer Drug Market Research and Analysis By Region, 2025-2035 ($ Million)
5. Global Prostate Cancer Drug Market Research and Analysis By Region, 2025-2035 ($ Million)
6. Global Blood Cancer Drug Market Research and Analysis By Region, 2025-2035 ($ Million)
7. Global Liver Cancer Drug Market Research and Analysis By Region, 2025-2035 ($ Million)
8. Global Others Cancer Drug Market Research and Analysis By Region, 2025-2035 ($ Million)
9. Global Oncology Drug Market Research and Analysis By Therapy, 2025-2035 ($ Million)
10. Global Chemotherapy Drug Market Research and Analysis By Region, 2025-2035 ($ Million)
11. Global Oncology Targeted Therapy Drug Market Research and Analysis By Region, 2025-2035 ($ Million)
12. Global Oncology Immunotherapy Drug Market Research and Analysis By Region, 2025-2035 ($ Million)
13. Global Oncology Hormonal Therapy Drug Market Research and Analysis By Region, 2025-2035 ($ Million)
14. Global Oncology Drug Market Research and Analysis By Molecule Type, 2025-2035 ($ Million)
15. Global Small Molecules Oncology Drug Market Research and Analysis By Region, 2025-2035 ($ Million)
16. Global Biologics Oncology Drug Market Research and Analysis By Region, 2025-2035 ($ Million)
17. Global Oncology Drug Market Research and Analysis By Region, 2025-2035 ($ Million)
18. North American Oncology Drug Market Research and Analysis By Country, 2025-2035 ($ Million)
19. North American Oncology Drug Market Research and Analysis By Cancer Type, 2025-2035 ($ Million)
20. North American Oncology Drug Market Research and Analysis By Therapy, 2025-2035 ($ Million)
21. North American Oncology Drug Market Research and Analysis By Molecule Type, 2025-2035 ($ Million)
22. European Oncology Drug Market Research and Analysis By Country, 2025-2035 ($ Million)
23. European Oncology Drug Market Research and Analysis By Cancer Type, 2025-2035 ($ Million)
24. European Oncology Drug Market Research and Analysis By Therapy, 2025-2035 ($ Million)
25. European Oncology Drug Market Research and Analysis By Molecule Type, 2025-2035 ($ Million)
26. Asia-Pacific Oncology Drug Market Research and Analysis By Country, 2025-2035 ($ Million)
27. Asia-Pacific Oncology Drug Market Research and Analysis By Cancer Type, 2025-2035 ($ Million)
28. Asia-Pacific Oncology Drug Market Research and Analysis By Therapy, 2025-2035 ($ Million)
29. Asia-Pacific Oncology Drug Market Research and Analysis By Molecule Type, 2025-2035 ($ Million)
30. Rest of the World Oncology Drug Market Research and Analysis By Country, 2025-2035 ($ Million)
31. Rest of the World Oncology Drug Market Research and Analysis By Cancer Type, 2025-2035 ($ Million)
32. Rest of the World Oncology Drug Market Research and Analysis By Therapy, 2025-2035 ($ Million)
33. Rest of the World Oncology Drug Market Research and Analysis By Molecule Type, 2025-2035 ($ Million)
1. Global Oncology Drug Market Research and Analysis By Cancer Type, 2025 Vs 2035 (%)
2. Global Lung Cancer Drug Market Research and Analysis By Region, 2025 Vs 2035 (%)
3. Global Breast Cancer Drug Market Research and Analysis By Region, 2025 Vs 2035 (%)
4. Global Colorectal Cancer Drug Market Research and Analysis By Region, 2025 Vs 2035 (%)
5. Global Prostate Cancer Drug Market Research and Analysis By Region, 2025 Vs 2035 ($ Million)
6. Global Blood Cancer Drug Market Research and Analysis By Region, 2025 Vs 2035 ($ Million)
7. Global Liver Cancer Drug Market Research and Analysis By Region, 2025 Vs 2035 ($ Million)
8. Global Others Cancer Drug Market Research and Analysis By Region, 2025 Vs 2035 ($ Million)
9. Global Oncology Drug Market Research and Analysis By Therapy, 2025 Vs 2035 (%)
10. Global Chemotherapy Drug Market Research and Analysis By Region, 2025 Vs 2035 (%)
11. Global Oncology Targeted Therapy Drug Market Research and Analysis By Region, 2025 Vs 2035 (%)
12. Global Oncology Immunotherapy Drug Market Research and Analysis By Region, 2025 Vs 2035 (%)
13. Global Oncology Hormonal Therapy Drug Market Research and Analysis By Region, 2025 Vs 2035 ($ Million)
14. Global Oncology Drug Market Research and Analysis By Molecule Type, 2025 Vs 2035 ($ Million)
15. Global Small Molecules Oncology Drug Market Research and Analysis By Region, 2025 Vs 2035 ($ Million)
16. Global Biologics Oncology Drug Market Research and Analysis By Region, 2025 Vs 2035 ($ Million)
17. US Oncology Drug Market Size, 2025-2035 ($ Million)
18. Canada Oncology Drug Market Size, 2025-2035 ($ Million)
19. UK Oncology Drug Market Size, 2025-2035 ($ Million)
20. France Oncology Drug Market Size, 2025-2035 ($ Million)
21. Germany Oncology Drug Market Size, 2025-2035 ($ Million)
22. Italy Oncology Drug Market Size, 2025-2035 ($ Million)
23. Spain Oncology Drug Market Size, 2025-2035 ($ Million)
24. Russia Oncology Drug Market Size, 2025-2035 ($ Million)
25. Rest of Europe Oncology Drug Market Size, 2025-2035 ($ Million)
26. India Oncology Drug Market Size, 2025-2035 ($ Million)
27. China Oncology Drug Market Size, 2025-2035 ($ Million)
28. Japan Oncology Drug Market Size, 2025-2035 ($ Million)
29. South Korea Oncology Drug Market Size, 2025-2035 ($ Million)
30. Australia and New Zealand Oncology Drug Market Size, 2025-2035 ($ Million)
31. ASEAN Economies Oncology Drug Market Size, 2025-2035 ($ Million)
32. Rest of Asia-Pacific Oncology Drug Market Size, 2025-2035 ($ Million)
33. Latin America Oncology Drug Market Size, 2025-2035 ($ Million)
34. Middle East and Africa Oncology Drug Market Size, 2025-2035 ($ Million)
- Printable version
- No restriction to number of users within the company
